DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

ISPOR Europe 2019

Saturday, November 02, 2019 - Wednesday, November 06, 2019

Copenhagen, Denmark

Mark your Calendar

ISPOR is the leading scientific and educational organization for HEOR and its use in healthcare decision-making. ISPOR Europe 2019 will bring together more than 5000 global healthcare leaders creating an energizing meeting ground for sound science, robust methodology, relevant policy discussions, and multi-stakeholder perspectives.

Decision Resources Group will be contributing new research spanning the product development lifecycle all focused on supporting optimal patient access and reimbursement. Visit our team of experts at booth #C3-059.

Schedule a Meeting

 

ISPOR Europe 2019 Poster Presentation Schedule

Monday, 4 November

PNS369: RECOMMENDATIONS FOR CONDUCTING COGNITIVE INTERVIEWS REMOTELY TO DEVELOP CLINICAL OUTCOME ASSESSMENTS

PCN198: FRACTIONAL POLYNOMIAL MODELS FOR NETWORK META-ANALYSIS OF SURVIVAL DATA IN ECONOMIC EVALUATIONS: A CASE-STUDY ON THE COST-EFFECTIVENESS OF FULVESTRANT IN PREVIOUSLY-TREATED POSTMENOPAUSAL, OESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER

PCN179: TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS

PCN283: DECISION DIVERGENCE BETWEEN FDA & EMA FOR BIO-PHARMACEUTICAL PRODUCTS IN ONCOLOGY DUE TO SINGLE-ARM TRIALS

PCN335: DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

PCN369: WHAT IS THE REGULATORY AND HTA LANDSCAPE OF NON-SMALL CELL LUNG CANCER DRUGS ACROSS THE EU5 COUNTRIES?

Tuesday, 5 November

PDB80: DIABETIC MACULAR EDEMA IN EUROPE: THE IMPACT OF PAYER POLICY ON PRESCRIBING

PMU113: IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS?

PCV106: ANTIHYPERTENSIVE AGENT UTILIZATION AMONG PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE UNITED STATES

PMU126: BIO-PHARMACEUTICAL PRODUCT CHARACTERISTICS IDEAL FOR INNOVATIVE ACCESS AGREEMENTS (IAA)

PMU96: ICER AND NICE EVALUATIONS - ARE THERE ANY CROSS-BORDER IMPACT ON DECISIONS?

Wednesday, 6 November

PRO84: REGULATORY AND MARKET ACCESS LANDSCAPE FOR CYSTIC FIBROSIS

PRO87: RARITY OF CROSS-OVER TRIALS IN RARE DISEASES: PAYER EDUCATION REMAINS CRITICAL IN EU

PRO88: PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5

PRO90: TRENDS IN PRICING OF RARE DISEASE TREATMENTS PRE- AND POST-PAYER EVALUATION IN GERMANY

PRO117: ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

PGI42: THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM?

PGI46: DISEASE BURDEN, SYMPTOMS ASSOCIATED WITH TREATMENT-SEEKING AND REMISSION DEFINITION: A QUALITATIVE STUDY IN ADULT AND ADOLESCENT PATIENTS WITH CROHN'S DISEASE

PBI47: PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA